---
title: "Shenzhen Chipscreen Biosciences' Drug Gets NMPA's Nod for Clinical Trials"
date: "2025-02-10 15:20:34"
summary: "Shenzhen Chipscreen Biosciences said its drug Chidamide received clinical trial approval from China's National Medical Products Administration (NMPA), according to a Friday filing with the Shanghai Bourse. The trial will evaluate Chidamide combined with CHOP therapy for newly diagnosed PTCL/TFH patients in a Phase III, randomized, double-blind, placebo-controlled, multi-center study...."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Shenzhen Chipscreen Biosciences said its drug Chidamide received clinical trial approval from China's National Medical Products Administration (NMPA), according to a Friday filing with the Shanghai Bourse.

The trial will evaluate Chidamide combined with CHOP therapy for newly diagnosed PTCL/TFH patients in a Phase III, randomized, double-blind, placebo-controlled, multi-center study. Chidamide, an HDAC inhibitor, has previously been approved for multiple cancer treatments in China, Japan, and Taiwan.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:G2465553:0/)
